Cardiovascular health and life expectancy free of atherosclerotic cardiovascular disease among patients with type 2 diabetes: a cohort study
Authors' conclusion
Higher levels of CVH in individuals with diabetes extend their life expectancy free from ASCVD, bringing it closer to that of individuals without diabetes.
Study context
- Population
- UK Biobank adults with and without T2DM10,579 (4.3%) with T2DM
- Participants
- 246,183 adults
- Exposure
- Low vs moderate vs high cardiovascular health (CVH) in T2DM, vs no T2DM
- Outcome
- Life expectancy free of ASCVD
- Follow-up
- At age 40
Methodological detailsUK Biobank, T2DM: mean follow-up 11.6 years for atherosclerotic cardiovascular disease (ASCVD), 5.0 years for mortality after ASCVD; 2211 new ASCVD cases, 591 deaths post-diagnosis
- UK Biobank
- T2DM: mean follow-up 11.6 years for ASCVD, 5.0 years for mortality after ASCVD; 2211 new ASCVD cases, 591 deaths post-diagnosis
Main finding
As reported in the abstract
ASCVD-free life expectancy at age 40, T2DM by CVH level vs non-diabetic
Observational data: associations, not effects.
Further findings
Percent
Low CVH (women)
87.5%(95% CI 87.1%–87.9%)
Ideal CVH (women)
89.6%(95% CI 89.2%–89.9%)
Without T2DM (women)
89.7%(95% CI 89.4%–90.0%)
Low CVH (men)
82.9%(95% CI 82.4%–83.4%)
Ideal CVH (men)
85.6%(95% CI 85.2%–86.0%)
Without T2DM (men)
84.4%(95% CI 84.0%–84.8%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Cardiovascular health and life expectancy free of atherosclerotic cardiovascular disease among patients with type 2 diabetes: a cohort study. Eur J Prev Cardiol. Published 24 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →